Maximus, Inc. (NYSE:MMS) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Wednesday. The firm currently has a $73.00 price objective on the health services provider’s stock. Zacks Investment Research‘s price objective points to a potential upside of 11.26% from the stock’s current price.

According to Zacks, “MAXIMUS, Inc. is an extremely dynamic and complex organization that offers government and industry a range of unique services, products, and solutions. The diverse services and products that MAXIMUS offers may be categorized into three groups: Government Program Management and Operations, Consulting, and Systems. Government Program Management and Operations focuses on having a measurable impact on the lives of the citizens we help government serve. The insights of MAXIMUS Consulting, and the technological innovations advanced through Systems, help government gain program efficiencies and pursue improvements that in turn benefit citizens. “

Several other equities research analysts also recently issued reports on the company. BidaskClub downgraded Maximus from a “strong-buy” rating to a “buy” rating in a research report on Thursday, July 6th. Canaccord Genuity lowered Maximus from a “buy” rating to a “hold” rating and set a $62.00 price objective on the stock. in a research note on Tuesday, July 4th. Robert W. Baird reissued a “hold” rating and set a $64.00 price objective on shares of Maximus in a research report on Friday, September 1st. Finally, Maxim Group set a $66.00 price objective on Maximus and gave the stock a “hold” rating in a research report on Thursday, August 3rd. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating and one has assigned a buy rating to the stock. The company presently has an average rating of “Hold” and an average target price of $63.14.

Shares of Maximus (NYSE:MMS) opened at 65.61 on Wednesday. The firm’s 50-day moving average price is $61.94 and its 200-day moving average price is $61.74. Maximus has a 52 week low of $43.69 and a 52 week high of $65.87. The firm has a market cap of $4.26 billion, a price-to-earnings ratio of 21.03 and a beta of 1.36.

Maximus (NYSE:MMS) last announced its earnings results on Thursday, August 3rd. The health services provider reported $0.79 EPS for the quarter, topping the consensus estimate of $0.76 by $0.03. The firm had revenue of $600.40 million for the quarter, compared to the consensus estimate of $614.12 million. Maximus had a net margin of 8.43% and a return on equity of 25.08%. The business’s quarterly revenue was down 2.7% on a year-over-year basis. During the same quarter last year, the firm posted $0.79 EPS. Equities research analysts expect that Maximus will post $3.13 EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Maximus, Inc. (MMS) Stock Rating Upgraded by Zacks Investment Research” was originally posted by American Banking News and is owned by of American Banking News. If you are reading this piece of content on another domain, it was illegally stolen and reposted in violation of international copyright & trademark law. The original version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/10/04/maximus-inc-mms-stock-rating-upgraded-by-zacks-investment-research.html.

In related news, President Bruce Caswell sold 8,000 shares of the stock in a transaction dated Wednesday, July 12th. The shares were sold at an average price of $62.21, for a total value of $497,680.00. Following the completion of the sale, the president now owns 35,904 shares in the company, valued at $2,233,587.84. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, General Counsel David Francis sold 1,000 shares of Maximus stock in a transaction dated Friday, July 14th. The stock was sold at an average price of $60.46, for a total value of $60,460.00. Following the sale, the general counsel now directly owns 15,715 shares in the company, valued at $950,128.90. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 157,403 shares of company stock worth $9,716,341. Insiders own 3.10% of the company’s stock.

A number of institutional investors have recently bought and sold shares of the business. BlackRock Inc. lifted its position in shares of Maximus by 22,491.0% in the 1st quarter. BlackRock Inc. now owns 6,503,511 shares of the health services provider’s stock worth $404,518,000 after acquiring an additional 6,474,723 shares during the period. Vanguard Group Inc. increased its position in shares of Maximus by 2.4% during the second quarter. Vanguard Group Inc. now owns 5,669,026 shares of the health services provider’s stock valued at $355,052,000 after purchasing an additional 130,839 shares during the period. FMR LLC increased its position in shares of Maximus by 10.4% during the second quarter. FMR LLC now owns 4,658,584 shares of the health services provider’s stock valued at $291,767,000 after purchasing an additional 438,025 shares during the period. William Blair Investment Management LLC increased its position in shares of Maximus by 14.7% during the first quarter. William Blair Investment Management LLC now owns 4,416,279 shares of the health services provider’s stock valued at $274,693,000 after purchasing an additional 566,292 shares during the period. Finally, BlackRock Fund Advisors increased its position in shares of Maximus by 5.8% during the third quarter. BlackRock Fund Advisors now owns 3,467,255 shares of the health services provider’s stock valued at $196,108,000 after purchasing an additional 190,375 shares during the period. 97.23% of the stock is owned by hedge funds and other institutional investors.

Maximus Company Profile

MAXIMUS, Inc provides business process services (BPS) to government health and human services agencies. The Company operates through three segments: U.S. Federal Services, Health Services and Human Services. The U.S. Federal Services segment provides BPS and program management for large government programs, independent health review and appeals services for both the United States Federal Government, and state-based programs and technology solutions for civilian federal programs.

Get a free copy of the Zacks research report on Maximus (MMS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Maximus (NYSE:MMS)

Receive News & Ratings for Maximus Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Maximus Inc. and related companies with MarketBeat.com's FREE daily email newsletter.